Form 8-K - Current report:
SEC Accession No. 0001193125-25-116443
Filing Date
2025-05-09
Accepted
2025-05-09 07:05:06
Documents
16
Period of Report
2025-05-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d27625d8k.htm   iXBRL 8-K 27232
2 EX-99.1 d27625dex991.htm EX-99.1 60127
3 EX-99.2 d27625dex992.htm EX-99.2 18341
7 GRAPHIC g27625g0507213505531.jpg GRAPHIC 3519
  Complete submission text file 0001193125-25-116443.txt   252261

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA kymr-20250509.xsd EX-101.SCH 2852
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE kymr-20250509_lab.xml EX-101.LAB 17993
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kymr-20250509_pre.xml EX-101.PRE 11262
18 EXTRACTED XBRL INSTANCE DOCUMENT d27625d8k_htm.xml XML 3646
Mailing Address 500 NORTH BEACON STREET, 4TH FLOOR WATERTOWN MA 02472
Business Address 500 NORTH BEACON STREET, 4TH FLOOR WATERTOWN MA 02472 857-285-5314
Kymera Therapeutics, Inc. (Filer) CIK: 0001815442 (see all company filings)

EIN.: 812992166 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39460 | Film No.: 25928334
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)